154 related articles for article (PubMed ID: 38292042)
1. Efficacy and safety of pegzilarginase in arginase 1 deficiency (PEACE): a phase 3, randomized, double-blind, placebo-controlled, multi-centre trial.
Russo RS; Gasperini S; Bubb G; Neuman L; Sloan LS; Diaz GA; Enns GM;
EClinicalMedicine; 2024 Feb; 68():102405. PubMed ID: 38292042
[TBL] [Abstract][Full Text] [Related]
2. Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency.
Diaz GA; Schulze A; McNutt MC; Leão-Teles E; Merritt JL; Enns GM; Batzios S; Bannick A; Zori RT; Sloan LS; Potts SL; Bubb G; Quinn AG
J Inherit Metab Dis; 2021 Jul; 44(4):847-856. PubMed ID: 33325055
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review.
Bin Sawad A; Jackimiec J; Bechter M; Trucillo A; Lindsley K; Bhagat A; Uyei J; Diaz GA
Mol Genet Metab; 2022; 137(1-2):153-163. PubMed ID: 36049366
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
6. Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth.
Badeaux MD; Rolig AS; Agnello G; Enzler D; Kasiewicz MJ; Priddy L; Wiggins JF; Muir A; Sullivan MR; Van Cleef J; Daige C; Vander Heiden MG; Rajamanickam V; Wooldridge JE; Redmond WL; Rowlinson SW
Cancer Immunol Res; 2021 Apr; 9(4):415-429. PubMed ID: 33500272
[TBL] [Abstract][Full Text] [Related]
7. Preclinical safety and antitumor activity of the arginine-degrading therapeutic enzyme pegzilarginase, a PEGylated, cobalt-substituted recombinant human arginase 1.
Agnello G; Alters SE; Rowlinson SW
Transl Res; 2020 Mar; 217():11-22. PubMed ID: 31954097
[TBL] [Abstract][Full Text] [Related]
8. Natural history of arginase 1 deficiency and the unmet needs of patients: A systematic review of case reports.
Bin Sawad A; Pothukuchy A; Badeaux M; Hodson V; Bubb G; Lindsley K; Uyei J; Diaz GA
JIMD Rep; 2022 Jul; 63(4):330-340. PubMed ID: 35822089
[TBL] [Abstract][Full Text] [Related]
9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.
Schoser B; Roberts M; Byrne BJ; Sitaraman S; Jiang H; Laforêt P; Toscano A; Castelli J; Díaz-Manera J; Goldman M; van der Ploeg AT; Bratkovic D; Kuchipudi S; Mozaffar T; Kishnani PS;
Lancet Neurol; 2021 Dec; 20(12):1027-1037. PubMed ID: 34800400
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of leriglitazone for preventing disease progression in men with adrenomyeloneuropathy (ADVANCE): a randomised, double-blind, multi-centre, placebo-controlled phase 2-3 trial.
Köhler W; Engelen M; Eichler F; Lachmann R; Fatemi A; Sampson J; Salsano E; Gamez J; Molnar MJ; Pascual S; Rovira M; Vilà A; Pina G; Martín-Ugarte I; Mantilla A; Pizcueta P; Rodríguez-Pascau L; Traver E; Vilalta A; Pascual M; Martinell M; Meya U; Mochel F;
Lancet Neurol; 2023 Feb; 22(2):127-136. PubMed ID: 36681445
[TBL] [Abstract][Full Text] [Related]
13. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A
CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Rothenberg ME; Dellon ES; Collins MH; Hirano I; Chehade M; Bredenoord AJ; Lucendo AJ; Spergel JM; Sun X; Hamilton JD; Mortensen E; Laws E; Maloney J; Mannent LP; McCann E; Liu X; Glotfelty L; Shabbir A
Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):990-1004. PubMed ID: 37660704
[TBL] [Abstract][Full Text] [Related]
18. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
19. The role and control of arginine levels in arginase 1 deficiency.
Diaz GA; Bechter M; Cederbaum SD
J Inherit Metab Dis; 2023 Jan; 46(1):3-14. PubMed ID: 36175366
[TBL] [Abstract][Full Text] [Related]
20. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
